European Patent Office

T 1503/21 (Combination Tablet/ASTRAZENECA) of 29.02.2024

European Case Law Identifier
ECLI:EP:BA:2024:T150321.20240229
Date of decision
29 February 2024
Case number
T 1503/21
Petition for review of
-
Application number
10782116.7
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
IMMEDIATE RELEASE TABLET FORMULATIONS
Applicant name
AstraZeneca AB
AstraZeneca UK Limited
Opponent name
Hoefer & Partner Patentanwälte mbB
STADA Arzneimittel AG
Generics (U.K.) Limited
Galenicum Health S.L.U.
Board
3.3.07
Headnote
-
Relevant legal provisions
European Patent Convention Art 123(2)European Patent Convention Art 56European Patent Convention Art 83European Patent Convention Art 84Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 012(6)Rules of procedure of the Boards of Appeal 2020 Art 013(1)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
Keywords
Inventive step - main request, auxiliary requests 1c, 2-6, 11b, 11c, 12-16 (no)
Inventive step - auxiliary request 17 (yes)
Amendments - auxiliary requests 7-9
Amendments - allowable (no)
Amendments - auxiliary request 17
Amendments - allowable (yes)
Claims - clarity
Claims - auxiliary request 17 (yes)
Sufficiency of disclosure - auxiliary reqeust 17 (yes)
Amendment to case - exercise of discretion
Catchword
-
Cited cases
T 1287/14
Citing cases
-

Order

For these reasons it is decided that:

1. The decision under appeal is set aside

2. The case is remitted to the opposition division with the order to maintain the patent in amended form based on the claims of the auxiliary request 17 as filed with the reply of the appellants (patent proprietors) on March 2022 and a description to be adapted thereto.